FDA OKs MRIMath’s Cyber Device and AI Solution for Glioblastoma

MRIMath, an artificial intelligence (AI) company funded by the National Cancer Institute, has earned U.S. Food and Drug Administration (FDA) clearance for its MRIMath i2Contour cyber device and AI to boost glioblastoma (GBM) management.
 
The company said the tool can save physicians up to an hour per imaging study, reducing bottlenecks in contouring. The i2Contour device features AI-powered and smart tools to streamline segmentation.
 
GBM labeling and volume measurement time are reduced by up to an hour and it’s compliant with FDA safety measures for safe medical data management. Precise labeling of GBM MRI FLAIR and T1 contrast (T1c) sequences support clinical decision making, as well.
 
Smart manual contouring lowers inter-user variability and facilitates review and approval processes. Volume measurement and plotting provide tools for precise monitoring over time and treatment planning.
 
MRIMath AI models yielded a labeling accuracy of 95% for T1c and 92% for FLAIR that align with radiologists’ scores in accuracy testing submitted to the FDA. The MRIMath Smart manual contouring platform demonstrated under 5% inter-user variability between radiologists for T1c and under 10% for FLAIR sequences. Furthermore, the AI models produced precise volume measurements and variability scores that align very closely with those measured by radiologists.
 
“This is truly a game-changer for a busy CNS radiation oncology practice. After thorough evaluation, I find it easy to learn, user-friendly, and seamlessly integrates into my workflow. Radiation oncologists often spend a significant amount of time contouring using manual platforms, which can result in substantial inter-user variability. The MRIMath Smart Contouring software is a breath of fresh air, offering low-variability, effective, and precise auto-contouring features. The MRIMath cyber device and AI streamline complex treatment planning workflows with high precision and robustness. The innovative features of MRIMath i2Contour will undoubtedly improve quality and advance patient care while also having the potential to lower healthcare costs,” said Markus Bredel, MD, Ph.D., Chairman and Sylvester Professor of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida.